Loading ......
Ketamine ((R, S)-ketamine) is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist with unique molecular biological characteristics and mechanisms of action. Its chemical formula is C13H16ClNO, with a molecular weight of 274.4. Ketamine consists of two optical isomers: S(+)ketamine and R(-)ketamine. An asymmetric carbon atom at the C2 position in its molecular structure gives ketamine its chirality.
Ketamine's structure is phenylcyclohexylamine, similar to phencyclidine (PCP), containing a cyclohexanone group. Its mechanism of action primarily involves non-competitive antagonism of the NMDA receptor. Among the isomers, S(+)ketamine is twice as potent as the racemic mixture and four times as potent as R(-)ketamine in NMDA receptor efficacy. Ketamine acts as an open channel blocker, binding to specific sites within the NMDA receptor channel, reducing the channel's open frequency and decreasing the average open time. Additionally, ketamine affects various other targets, including α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors and sigma-1 receptors, contributing to its unique effects and applications.
Ketamine is mostly metabolized by cytochrome P450 enzymes in the liver, specifically CYP3A4, CYP2B6, and CYP2C9. These enzymes convert ketamine to norketamine, which is then metabolized into 4-, 5-, and 6-hydroxy-norketamine. Ketamine's bioavailability via intravenous injection is 100%, whereas intramuscular injection is slightly lower, at roughly 93%. Ketamine's high lipid solubility enables quick absorption by the brain, with a distribution half-life of only 10-15 minutes and a volume of distribution of around 3 L/kg. Ketamine's inactive metabolites and conjugates are removed by the kidneys, with a half-life of 2-3 hours. Although the body converts ketamine into the active metabolite norketamine, its potency is one-third that of ketamine.
Ketamine's mechanism of action is closely linked to its non-competitive blockage of the NMDA receptor, which effectively generates a dissociative state in which patients retain airway reflexes and respiratory drive but are insensitive to sensory information.
Figure 1. Structure of ketamine and its role as an NMDA receptor antagonist.
(Source: Kohtala S, 2021)
Ketamine was brought into clinical practice in the 1960s and has been used in operating rooms for nearly 50 years. Ketamine is often used to produce and maintain anesthesia in patients with asthma and acute bronchoconstriction due to its exceptional bronchial dilation properties. Ketamine is a good anesthetic for hemodynamically unstable patients because it activates the central sympathetic nervous system.
Ketamine is characterized by "dissociative anesthesia," where patients may appear awake while retaining airway reflexes and respiratory drive. Not only does ketamine perform well in anesthesia induction, but its good analgesic effects also make it a popular anesthetic among various patient groups. The advantages of ketamine include multiple routes of administration, such as intravenous, intramuscular, and nasal, meeting different clinical needs. In clinical applications, ketamine is administered at a dose of 0.5-1 mg/kg for general anesthesia induction, with maintenance achieved through repeated dosing. Sub-anesthetic doses (0.2-0.8 mg/kg IV or 2-4 mg/kg IM) can also produce good analgesic and sedative effects.
Ketamine's anesthetic effects are principally produced through its numerous interactions with the central nervous system. First, ketamine inhibits glutamate excitatory transmission by antagonizing NMDA receptors, resulting in sensation and perceptual separation. Ketamine also amplifies the effects of gamma-aminobutyric acid (GABA), which further inhibits central nervous system activity. Ketamine also acts on the endogenous opioid system, with studies indicating that it can reduce pain by boosting the release of endogenous opioid peptides. Ketamine inhibits autonomic nervous system reactions and lowers respiratory secretions by decreasing acetylcholine release, making anesthesia safer and more comfortable. Ketamine's impact on the central dopamine system may also contribute to its analgesic and psychoactive effects. Through these multiple pathways, ketamine achieves efficient anesthesia. Additionally, S(+)-ketamine is considered more effective than the R(-)-isomer in terms of anesthesia and analgesia, with its anesthetic potency being three to four times that of the R(-)-isomer.
Figure 2. Sites of action of ketamine and other drugs in the pain signaling pathway.
(Source: Gorlin AW, et al. 2016)
The perioperative application of ketamine requires attention to possible side effects, including postoperative nausea, vomiting, elevated heart rate, and blood pressure fluctuations. When using ketamine, clinicians should be cautious of potential increased intracranial pressure, especially in patients with space-occupying brain lesions or brain injuries. Slow injection of ketamine can reduce central respiratory impacts and minimize the risk of transient respiratory arrest associated with rapid injection.
Initially developed as an anesthetic, ketamine's potential in treating depression has garnered increasing attention in recent years. Ketamine's antidepressant mechanism is primarily through its antagonism of NMDA receptors, effectively increasing certain neurotransmitter levels in the brain and promoting synaptic plasticity. Additionally, ketamine may affect other signaling pathways, improving depressive symptoms. Clinically, sub-anesthetic doses of ketamine, around 0.5 mg/kg, are typically used for intervention, effectively improving depressive states.
Unlike traditional antidepressants, ketamine acts fast and significantly in people with major depressive disorder (MDD), generally reducing suicidal ideation within two hours, providing a novel approach to treating severe depression. TRD is characterized as depression that does not respond to at least two types of antidepressants. Ketamine has had tremendous success in TRD patients, particularly when other treatments have failed. Ketamine has been found in tests to rapidly restore synaptic plasticity and neuronal function, hence relieving TRD symptoms. A single dose of ketamine can significantly reduce suicidal ideation within hours, with the benefits lasting for days. Ketamine's rapid onset makes it a useful emergency remedy, especially since traditional antidepressants take weeks to become effective.
In addition to severe depression, ketamine has been explored for the treatment of other mental diseases such as bipolar disorder, post-traumatic stress disorder (PTSD), and anxiety disorders. Ketamine shows substantial antidepressant effects in bipolar disorder patients, whereas it alleviates post-traumatic symptoms and improves the quality of life in PTSD patients, indicating intriguing therapeutic potential.
Figure 3. Proposed signaling pathway for the antidepressant effects of ketamine.
(Source: Jelen LA., et al. 2021)
While ketamine has broad therapeutic potential, its side effects must not be overlooked. The side effects of ketamine can be categorized into physiological and psychological aspects, especially with long-term use or abuse, which may lead to severe adverse reactions.
Ketamine's psychological side effects are highly noticeable. After the initial usage, patients frequently have "dissociative experiences," in which they feel separated from themselves or their surroundings, with altered perceptions of time and space, resulting in panic or anxiety. Ketamine at high dosages can also cause hallucinations and delusions, with patients seeing or hearing things that do not exist or holding absurd ideas. These symptoms are more common in ketamine misuse and can progress to schizophrenia-like psychotic behavior. Ketamine can create emotional instability in patients, ranging from tremendous exhilaration to deep sadness. Long-term use of ketamine may result in cognitive impairment, including memory loss, reduced attention, and executive function disorders. These cognitive issues can significantly impact a patient's work and learning, with some damage potentially being irreversible.
Aside from psychological side effects, ketamine's physiological adverse effects are significant, particularly during the perioperative phase and after long-term use. Although ketamine has good bronchial dilation capabilities in anesthetic induction, excessive dosages might cause respiratory depression or apnea. This danger increases with rapid infusion, necessitating close monitoring of the patient's respiratory condition. Rapid ketamine injection can also induce a rise in heart rate and blood pressure changes, which are especially noticeable in individuals with hypertension or heart disease and should be used with caution. Ketamine use can cause nausea, vomiting, and gastrointestinal discomfort, which are common in the early postoperative period and can typically be addressed with symptomatic medicine. However, long-term ketamine use or abuse can affect the urinary system, causing cystitis and renal failure. Patients may experience difficulties urinating, hematuria, and bladder pain; in severe cases, surgical intervention may be required.
Finally, because of its unusual chemical structure and various modes of action, ketamine has vast application prospects in anesthesia and the treatment of mental illnesses. Despite its high efficacy in treating major depressive disorder, treatment-resistant depression, and suicidal ideation, it is associated with possible adverse effects and misuse hazards. To guarantee safe and effective ketamine treatment, practitioners must properly assess the risks and benefits, design suitable treatment plans, and closely monitor patients' physiological and psychological states. Healthcare workers can improve their use of ketamine by studying its molecular biological properties, pharmacological mechanisms, therapeutic applications, and adverse effects. High-quality antigens, antibodies, and ELISA kits can support in-depth exploration of ketamine's potential applications and safety. We also offer a variety of products related to metabolites such as Norketamine, Dehydronorketamine, and Fluoroketamine. With comprehensive quality control products, Creative Diagnostic ensures your experiments are safeguarded. Please visit our product page for ordering.
References
| Target | Cat. No. | Product Name | Size | Application | Detection Sample | |
| Ketamine | DEIA-XYZ202 | Ketamine ELISA Kit | 96T | Qualitative | urine, blood, oral fluid | Inquiry |
| Target | Cat. No. | Product Name | Host | Isotype | Application | |
| Ketamine | DPAB27851 | Anti-Ketamine polyclonal antibody | Sheep | EIA, IA, ELISA, WB, Dot, IHC | Inquiry | |
| DMAB3849 | Anti-Ketamine monoclonal antibody, clone C925M | Mouse | IgG1 | WB, ELISA | Inquiry | |
| DPABY-885 | Anti-Ketamine polyclonal antibody | Sheep | Dot, ELISA, Pr*, IHC, WB | Inquiry | ||
| DMAB7675 | Mouse Anti-Ketamine monoclonal antibody, clone H12381N | Mouse | IgG1 | ELISA, LFIA | Inquiry |
| Target | Cat. No. | Product Name | Expression System | Tag/Conjugate | Application | |
| Ketamine | DAG1173 | Ketamine [HRP] | N/A | HRP | N/A | Inquiry |
| DAG400 | Ketamine [BSA] | N/A | BSA | ELISA | Inquiry | |
| DAGA-280K | Ketamine [KLH] | N/A | KLH | Immunogen | Inquiry |
| Target | Cat. No. | Product Name | Host | Isotype | Application | |
| Norketamine | DCABY-557 | Anti-Norketamine monoclonal antibody, clone O6.8G7.C20.C7.C3. | Sheep | IgG | ELISA | Inquiry |
| DMAB27408 | Anti-Norketamine Monoclonal antibody, clone NBC0020 | Sheep | ELISA, WB, Dot, IHC, IA | Inquiry | ||
| DPAB27727 | Anti-Dehyrdronorketamine polyclonal antibody | Sheep | EIA, IA, ELISA, WB, Dot, IHC | Inquiry |
| Target | Cat. No. | Product Name | Expression System | Tag/Conjugate | Application | |
| Norketamine | DAGA-313B | Norketamine [BSA] | N/A | BSA | LFIA | Inquiry |
| DAGA-313K | Norketamine [KLH] | N/A | KLH | Immunogen | Inquiry | |
| DAGB343 | Norketamine [HRP] | N/A | HRP | IA | Inquiry | |
| DAGA-250B | Dehyrdronorketamine [BSA] | N/A | BSA | LFIA | Inquiry | |
| DAGA-250K | Dehyrdronorketamine [KLH] | N/A | KLH | Immunogen | Inquiry |
| Target | Cat. No. | Product Name | Host | Isotype | Application | |
| Dehydronorketamine | CABT-Z418S | Sheep Anti-Dehydronorketamine Polyclonal Antibody | Sheep | IgG | IA | Inquiry |
| Target | Cat. No. | Product Name | Expression System | Tag/Conjugate | Application | |
| Dehydronorketamine | DAGB344 | Dehyrdronorketamine [HRP] | N/A | HRP | IA | Inquiry |
| DWT09 | Dehydronorketamine HCl Standard solution | N/A | KLH | Inquiry |
| Target | Cat. No. | Product Name | Expression System | Tag/Conjugate | Application | |
| Fluoroketamine | DAG-WT1863 | Fluoroketamine [BSA] | N/A | KLH | ELISA, LFIA | Inquiry |
Loading ......